WATERTOWN, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions, today announced that Daniel J. Hicklin, Ph.D., President and Chief Executive Officer and Randi Isaacs, M.D., Chief Medical Officer, both of Werewolf Therapeutics, ...

Experienced legal leader brings deep expertise in governance, strategic transactions, and risk management to support Vor Bio’s growthCAMBRIDGE, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced the appointment of Adi Osovsky, S.J.D. as General Counsel. Dr. Osovsky brings 17 years of corporate counsel and law firm experience in the biotechnology and pharmaceutical sectors. “We are delighte ...

BEIJING, Sept. 02, 2025 (GLOBE NEWSWIRE) -- TIAN RUIXIANG Holdings Ltd. (Nasdaq: TIRX) (the “Company”) today announced that it will implement a reverse stock split of its ordinary shares at a ratio of five (5) to one (1), The Company’s ordinary shares will begin trading on a split-adjusted basis on the Nasdaq Capital Market at that time under the same ticker symbol, TIRX, effective at the open of business on September 5, 2025. As part of the reverse stock split, the par value of the Company’s Class A and Cl ...

GREENWICH, Conn., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Oxford Lane Capital Corp. (NasdaqGS: OXLC) (the “Company”) reported that it expects to implement the previously announced 1-for-5 reverse stock split of its issued and outstanding shares of common stock, par value $0.01 per share (“Common Stock”), effective as of September 5, 2025, with trading to begin on a split-adjusted basis at market open on the following business day, September 8, 2025. As a result of the reverse stock split, every five shares of Co ...

Group 1 - RedCloud Holdings plc has signed a Joint Venture with Kayanat to transform Saudi Arabia's estimated $60 billion market for Fast Moving Consumer Goods (FMCG) [1][2] - The partnership aligns with Saudi Arabia's Vision 2030, utilizing AI-powered trading technology to enhance the digital exchange of FMCG products [2][4] - RedCloud Arabia will be jointly owned by RedCloud and Kayanat, headquartered in Riyadh, and plans to launch operations in Q4 2025 [3][4] Group 2 - The RedAI platform will facilitate efficient B2B purchases and inventory decisions for retailers, leveraging AI to analyze complex purchasing behaviors [5][6] - The joint venture aims to introduce greater transparency and efficiency to supply chains, empowering local brands to scale and compete globally [4][8] - Kayanat is focused on building local expertise and fostering a self-sustaining economy in alignment with Saudi Vision 2030 [7][8]

NORCROSS, Ga., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that the company management will participate in the H.C. Wainwright 27th Annual Global Investment Conference, taking place September 8-10, 2025 in New York, NY. H.C. Wainwright 27th Annual Global Investment ConferenceCompany presentation: September 8, 2025, at 1:00 PM ET. Webcast: HEREThe live and archived webcast will also be avai ...

PRINCETON, N.J., Sept. 02, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that the Company will participate in the 27th Annual H.C. Wainwright Global Investment Conference, to be held in New York, NY and virtually September 8-10, 2025. Frank Bedu-Addo, Ph.D., Chief Executive Officer, and Lars Boesgaard, Chief Financial Officer, w ...

SAN DIEGO, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the Morgan Stanley 23rd Annual Global Healthcare Conference being held at the Sheraton New York Times Square in New York, NY. Management will present on Tuesday, September 9, 2025, at 3:20 pm Eastern Time and will also participa ...

NEW YORK, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Critical Metals Corp. (Nasdaq: CRML) (“Critical Metals Corp” or the “Company”), a leading critical minerals mining company, today announced that Tanbreez Mining Greenland A/S (“Tanbreez”) is approximately 70% complete on the final stages of the Bankable Feasibility Study (BFS) for a 500,000 tons per annum mining and processing operation at the Tanbreez Rare Earth Project in South Greenland. The BFS is being led by Danish engineering firm NIRAS A/S (“NIRAS”), a glob ...

Core Viewpoint - Replimune Group, Inc. is engaging with the FDA to discuss the complete response letter for its Biologics License Application for RP1 in combination with nivolumab for advanced melanoma treatment, emphasizing the urgent need for access to this therapy in the melanoma community [1][3]. Company Overview - Replimune Group, Inc. is a clinical-stage biotechnology company founded in 2015, focused on developing novel oncolytic immunotherapies to transform cancer treatment [5]. - The company's lead product candidate, RP1, is based on a proprietary strain of herpes simplex virus engineered to enhance tumor killing potency and activate systemic anti-tumor immune responses [4][5]. FDA Interaction - A Type A meeting with the FDA has been scheduled to address the complete response letter concerning the BLA for RP1, with the company submitting a briefing book that responds to the FDA's concerns [1][2]. - The briefing book includes prior agreements on patient population, PD-1 resistance criteria, and additional data analysis from the BLA [2]. Community Support - The melanoma community, including physicians and patient advocacy groups, has highlighted the urgent need for RP1 due to limited effective treatment options available [3].